james v. snider, Ph.D., president of critical diagnostics
Prior to joining Critical Diagnostics, Dr. Snider spent over three years as the Executive Vice President of Business & Operations for IntelligentMD, an early-stage medical device company that focuses on the essential elements of disease diagnostics and therapeutic intervention. While at IntelligentMD he guided the company through three rounds of fundraising, staffing and resourcing for two product development projects and several business development deals. Prior to joining IntelligentMD, Dr. Snider spent eight years in a series of marketing and product development positions at Applied Biosystems.

Before his tenure at Applied Biosystems, Dr. Snider was a Senior Scientist at Biotech Research Laboratories, a contracts and service research company specializing in retroviral technologies. Dr. Snider performed his post-doctoral research as a fellow in the Biological Response Modifiers Program at the Frederick Cancer Research & Development Center of the National Cancer Institute. He holds a BS in chemistry from Grand Valley State University, a Ph.D. in chemistry from the University of South Carolina and an MBA in technology management from the University of Phoenix.

james l. januzzi, md
Dr. Januzzi is an Assistant Professor of Medicine at Harvard Medical School, and an Assistant Physican in the Division of Cardiology at the Massachusetts General Hospital, in Boston, where he is also the co-director of the Coronary Care Unit.

Dr. Januzzi is an active clinical researcher in the area of cardiac biomarkers, where he has published ground-breaking research in the optimal applications of amino-terminal pro-Brain natriuretic peptide testing. In addition, he has published extensively in the areas of troponin testing, as well as optimal management of patients with acute coronary syndromes, and acute aortic syndromes. He has published over 75 peer-reviewed manuscripts, review articles, and book chapters, and is on numerous editorial boards for prestigious journals. He lectures extensively on the value of cardiac biomarker testing for a broad range of cardiovascular syndromes. Lastly, Dr. Januzzi has an active cardiology practice, and serves as the cardiologist to the Boston Red Sox. Dr Januzzi was the top-ranked graduate of the New York Medical College in 1994.

robert l. jesse, md, Ph.D.
Dr. Robert Jesse received his B.S. degree in Biochemistry from the University of New Hampshire followed by a PhD in Biophysics at the Medical College of Virginia. After initially joining the basic sciences faculty in the Biophysics Department, he then went on to receive an MD degree followed by Internal Medicine Residency and Cardiology fellowship at the Medical College of Virginia campus at Virginia Commonwealth University. He is presently the Director of Acute Cardiac Care for Virginia Commonwealth University Health System, Chairman of the Cardiology Division at the Veteran Affairs Medical Center in Richmond, and National Program Director for Cardiology for the Veterans Health Administration in Washington, DC.

Dr. Jesse, along with the Acute Cardiac Team at VCUHS pioneered the nationally recognized Chest Pain Program, which has published widely on both the initial risk stratification and outcomes for patients with acute coronary syndromes, especially as related to biomarkers. Dr. Jesse has been the director of several national courses on the management of chest pain including the Society for Chest Pain Centers and Providers 6th Annual Meeting. He served on the National Academy of Clinical Biochemistry Task Force that authored the initial Standards of Laboratory Practice on the use of Cardiac Markers in 1999, and is presently on the committee rewriting those guidelines.

Dr. Jesse is a fellow of the American College of Cardiology, a regional governor for the Virginia Chapter of the ACC, and serves on the Quality Leadership Council. He is a fellow of the American Heart Association in both the Thrombosis, Atherosclerosis, and Vascular Biology Council and Clinical Cardiology Council, and is currently the President of the Richmond Metro Chapter of AHA. Dr Jesse serves on the National Cholesterol Education Program steering Committee, the National Heart Attack Alert Program steering committee, and on the NIH-NHLBI Advisory Council.

richard lee, md     
Richard T. Lee is Associate Professor of Medicine at Harvard Medical School and Associate Professor in the Division of Health Sciences and Technology at the Massachusetts Institute of Technology. Dr. Lee has published over 140 peer-reviewed articles based on his research, which combines approaches in biotechnology and molecular biology to discover new avenues to manage and treat heart disease. As a teacher, Dr. Lee has trained over 100 clinical and research fellows in cardiac imaging, and he directly supervises graduate students at M.I.T. In addition, Dr. Lee is an active clinician; he regularly treats patients as a cardiologist at Brigham and Women's Hospital, teaches clinical medicine to Harvard Medical students, and volunteers his time for medical care to the homeless at a Boston-area shelter.

alan stewart maisel, md
Dr. Maisel is a Professor of Medicine at the University of California, San Diego as well as the Director of the Coronary Care Unit and Heart Failure Program at the VA Medical Center in La Jolla, California. He is considered a world expert on cardiac biomarkers and has over 100 scientific publications. Dr. Maisel has authored several ground-breaking publications which have paved the way for BNP to become a diagnostic tool in congestive heart failure. He is active on the faculty at UCSD where he has won numerous teaching awards. Dr. Maisel was graduated with a Bachelor of Science in Psychology from Michigan State University, and was awarded a Doctor of Medicine degree from the University of Michigan School of Medicine. Dr. Maisel started his career at Michael Reese Hospital, where he rose to Chief Medical Resident. He has held positions as a Clinical Fellow, Cardiology Section and a Clinical Investigator at University of California, San Diego; Associate Investigator for the Veterans Administration Medical Center; Assistant Professor of Medicine, University of California San Diego; Director, Heart Station-Veterans Administration Medical Center; Assistant Professor of Medicine, University of California, San Diego; Director, Medical Intensive Care Unit, Veterans Administration Medical Center; and Associate Professor of Medicine, University of California, San Diego.

david a. morrow, md, mph
Dr. Morrow is a clinical investigator with the TIMI Study Group (a series of trials on improved treatments for coronary disease), and an Associate Physician in the Division of Cardiovascular Medicine at Brigham and Women's Hospital, Boston, MA. Dr. Morrow earned his medical degree from Harvard Medical School and a Masters in Public Health with a concentration in clinical study design and interpretation from the Harvard School of Public Health. He is currently an Assistant Professor of Medicine at Harvard Medical School. Dr. Morrow is an active investigator in the TIMI Study Group with a research focus on management of acute coronary syndromes, risk stratification in coronary artery disease and the clinical evaluation of novel biomarkers. He has been a major contributor to the development and expansion of the TIMI Study Group Biomarker Program. He sits on the National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines Committee on Biochemical Cardiac Markers for which he leads the clinical section on acute coronary syndromes. He also serves on the Program Committee of the Council on Clinical Cardiology of the American Heart Association and is on the Board of Editors for the journals Circulation and Clinical Chemistry. Dr. Morrow has more than 75 original scientific reports, reviews, editorials, book chapters and electronic publications in his areas of expertise.

william franklin peacock iv, md, facep
Dr. Peacock received his MD from Wayne State University in 1985 and completed his internship and residency in emergency medicine at William Beaumont Hospital in Michigan. After his training, he was attending staff at William Beaumont Hospital, and at the University of Michigan where he was an Assistant Professor. Ultimately, he was the Emergency Medicine Associate Residency Director at William Beaumont Hospital. In 1994, Dr. Peacock moved to Cleveland Ohio to assist in the development of a new department of emergency medicine at The Cleveland Clinic, where he is currently the Vice Chief of Emergency Medicine Research. He is also an Associate Professor at The Ohio State University, as well as the Medical Director for Event Medicine, which provides care to the stadiums of the Cleveland Browns, Cleveland Indians, and the Cleveland Gund Arena.

Dr. Peacock's academic focus has been in the research of emergency cardiology, where he has actively pursued the development and application of novel technologies for rendering care to emergency department patients. He has over 100 publications and has received substantial research grants in the areas of acute coronary syndromes and in heart failure management. In 2004, he received the "Award for Best Paper" at the Research Forum of the American College of Emergency Physicians. Recently, he was an integral member of the medical team that received the Codman Award in recognition for improvement in the delivery of care to heart failure patients. He is currently a member of the editorial board of the journal Congestive Heart Failure, was a past editor of the case report section in the journal "Topics in Emergency Medicine", and is the director of the annual Cleveland Clinic Emergency Cardiology conference.

Dr. Peacock is a fellow of the American College of Emergency Physicians, and among other offices, served as a member of the Board of Directors for the Michigan College of Emergency Physicians. He is also a member in the American Academy of Emergency Medicine, and the Society of Academic Emergency Medicine. He is a founding member of the Society of Chest Pain Centers and Providers, where he is the current chairman of the Heart Failure Educational Track for Annual Congress. He is also an active member in the Heart Failure Society of America and the American Heart Association, as well as many other professional organizations.

alan wu, Ph.D., D.A.B.C.C.
Alan H.B. Wu, Ph.D., is Chief of Clinical Chemistry and Toxicology at San Francisco General Hospital and Professor of Laboratory Medicine, University of California, San Francisco. Dr. Wu's research interest has been in the fields of biochemical markers for cardiovascular disease including CK-MB, myoglobin, troponin, B-type natriuretic peptide, markers of myocardial ischemia, and stroke. He has published over 300 papers, abstracts, and book chapters in this field. He is author of Cardiac Markers, Totowa Press, 1st and 2nd edition (1999 and 2003). He is a member of the National Academy of Clinical Biochemistry Laboratory Medicine Practice Guideline Committees on "Recommendations for the Use of Cardiac Markers in Coronary Artery Diseases." Dr. Wu has served on several editorial boards including Clinical Chemistry, Annals of Clinical Laboratory Science, Point of Care, and since 1998, he is co-editor-in-chief for Clinica Chimica Acta. He is a member of the AACC Standardization subcommittees on CK-MB and cardiac troponin, and the International Federation of Clinical Chemistry Stanrdardization of Markers of Cardiac Damage Committee. Dr. Wu received B.S. degrees in chemistry and biology at Purdue University, West Lafayette, Indiana, and a Ph.D. degree in analytical chemistry at the University of Illinois, Champaign-Urbana, Illinois. He completed a postdoctoral fellowship in clinical chemistry at Hartford Hospital. He is certified by the American Board of Clinical Chemistry in Clinical Chemistry and Toxicological Chemistry.

donna j. edmonds
Donna J. Edmonds brings over 30 years of experience in both the provider and the industry side of the healthcare business. Her primary focus has been in the introduction, management and commercialization of new and revolutionary technologies primarily in critical care areas for patient care. She has been a Hospital Administrator (Director of Nursing) and General Manager of a specialty physician group prior to her recruitment to industry. Her industry experience includes eight years with Baxter International in the Alternate Site, Diagnostics and Cardiovascular groups, the last four as a Vice President at the group level, where she held positions of increasing responsibility in Business Development, Sales and Marketing. She was the Senior Vice President, Market and Business Development for the Cardiovascular Strategic Business Unit of Inverness Medical Innovations, a public company with over $500M in revenue, following the acquisition of venture-backed Ischemia Technologies in early 2005, where she held a similar position. In December 2005 she organized the financing for and became the COO and SVP for Market Development for venture-backed Vital Sensors Inc, which is commercializing a sensor based cardiac pressure monitor. She is a Governor-appointed member of the Virginia Biotech Research Park Authority and a founding member of the Virginia Biosciences Development Center.

next >